How China’s rise as a biopharma innovation hub is reshaping global dealmaking strategies

GlobalData briefing: China biopharma drives global licensing growth, platform acquisitions, amid tightening US scrutiny. China’s biopharma ecosystem is reshaping how global pharmaceutical companies source innovation, build pipelines and structure deals. China’s biopharma rise: surging out-licensing values and platform acquisitions reshape global drug development amid tightening US regulatory and geopolitical scrutiny. Credit: Shutterstock A new Intelligence Briefing from GlobalData Healthcare suggests that China is becoming an increasingly strategic component of international growth strategies as Chinese-origin assets gain global validation and licensing values rise. According to the Briefing, entitled The Two-Way Street: From Stocking the Pipeline to Acquiring Development Platforms, The Next…

Source: Clinical Trials Arena